Related Experiment Videos
Watery diarrhoea syndrome with episodic hypercalcaemia
This study reports a patient with watery diarrhea and episodes of high blood calcium levels. The researchers found that the patient had elevated levels of a hormone called vasoactive intestinal peptide (VIP). After removing a tumor from the pancreas, VIP levels decreased and the patient’s symptoms went away. During a period of high calcium, the patient’s parathyroid hormone levels were low, suggesting that the high calcium was not caused by this hormone. The researchers propose that VIP may directly affect calcium levels and cause the symptoms. This case highlights the possible role of VIP in this rare condition and suggests that removing the tumor resolved the issue by reducing VIP levels.
Area of Science:
- Endocrinology and metabolic disorders
- Gastroenterology and digestive diseases
- Hormonal regulation in clinical medicine
Background:
Understanding the causes of watery diarrhea and hypercalcaemia remains a challenge in clinical endocrinology. It was already known that certain hormones influence calcium and fluid balance in the body. However, the specific role of vasoactive intestinal peptide (VIP) in these conditions was unclear. No prior work had resolved how VIP might contribute to both symptoms simultaneously. This gap motivated researchers to investigate a case where both watery diarrhea and hypercalcaemia occurred together. The patient's condition suggested a hormonal imbalance, but the exact mechanism was unknown. Prior research had shown that VIP affects intestinal secretion and calcium metabolism. That uncertainty drove the need to explore the connection between VIP and these clinical features. The goal was to determine whether VIP could be responsible for both symptoms in this patient.
Purpose Of The Study:
The aim of this study was to evaluate a patient with concurrent watery diarrhea and episodic hypercalcaemia. The researchers wanted to determine if vasoactive intestinal peptide (VIP) played a role in the patient’s symptoms. They hypothesized that VIP might be responsible for both the diarrhea and the hypercalcaemia. This hypothesis was based on the known effects of VIP on intestinal and calcium metabolism. The study sought to confirm whether VIP levels were elevated in this patient. They also aimed to assess the impact of removing a pancreatic islet cell adenoma on VIP levels and symptoms. The motivation stemmed from the lack of understanding of this rare clinical presentation. The researchers hoped to provide insight into the pathophysiology of this syndrome.
Main Methods:
The researchers measured plasma levels of vasoactive intestinal peptide (VIP) in the patient. They also assessed serum parathyroid hormone (PTh) levels during a hypercalcaemic episode. The patient underwent imaging and endoscopic evaluation to locate the source of VIP overproduction. A pancreatic islet cell adenoma was identified and surgically removed. Post-surgery, VIP levels were monitored to determine if they decreased. The researchers observed whether the patient’s symptoms resolved after the tumor removal. They compared VIP and PTh levels before and after the procedure. The study relied on clinical observation and biochemical measurements to evaluate the patient’s condition.
Main Results:
Elevated plasma levels of vasoactive intestinal peptide (VIP) were observed in the patient. Following removal of the pancreatic islet cell adenoma, VIP levels decreased significantly. The patient’s watery diarrhea ceased after the tumor was removed. During a hypercalcaemic episode, serum parathyroid hormone (PTh) levels were suppressed. This indicated that the hypercalcaemia was not caused by PTh. The researchers propose that VIP directly influenced calcium turnover in the body. The decrease in VIP levels correlated with the resolution of symptoms. These findings support a role for VIP in both diarrhea and hypercalcaemia in this case.
Conclusions:
The researchers conclude that vasoactive intestinal peptide (VIP) may be responsible for both watery diarrhea and episodic hypercalcaemia. The decrease in VIP levels after tumor removal suggests a direct link between VIP and the patient’s symptoms. The suppression of parathyroid hormone (PTh) during hypercalcaemia supports this conclusion. The findings suggest that VIP may act independently of PTh to affect calcium metabolism. The study highlights the importance of VIP in this rare clinical syndrome. The resolution of symptoms after tumor removal confirms the role of the islet cell adenoma. The researchers propose that VIP may influence calcium turnover directly. These results may help guide future investigations into VIP-related disorders.
Frequently Asked Questions
The researchers propose that VIP may directly influence calcium turnover, leading to hypercalcaemia, and also cause watery diarrhea through its effects on intestinal secretion.
The patient was diagnosed with elevated VIP levels and a pancreatic islet cell adenoma, identified through imaging and endoscopic evaluation.
PTh was measured to determine if the hypercalcaemia was PTh-dependent or if another factor, such as VIP, was responsible.
Removing the islet cell adenoma led to a decrease in VIP levels and the resolution of the patient’s symptoms.
Suppressed PTh levels indicated that the hypercalcaemia was not caused by PTh, suggesting a direct effect of VIP on calcium metabolism.
The authors propose that VIP may act independently of PTh to influence calcium turnover and cause both diarrhea and hypercalcaemia.